Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-06-20
2006-06-20
Kemmerer, Elizabeth (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S007200, C435S069100, C435S325000, C436S501000
Reexamination Certificate
active
07063954
ABSTRACT:
Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
REFERENCES:
patent: 5235036 (1993-08-01), Kornreich et al.
patent: 5663292 (1997-09-01), Rivier
patent: 5824771 (1998-10-01), Rivier
patent: 5844074 (1998-12-01), Rivier
patent: 5869450 (1999-02-01), Wei et al.
patent: 6670140 (2003-12-01), Isfort et al.
patent: 0 860 501 (1998-08-01), None
patent: WO 96/37223 (1996-11-01), None
patent: WO 97/00063 (1997-01-01), None
McDonnell J, et al. 1998. British Journal of Pharmacology, 125:717-726.
Dautzenberg, et al. 1997. Journal of Neurochemistry, 69:1640-1649.
T.M. Reyes, et al., “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors”,PNAS, Feb. 27, 2001, 2843-2848, vol. 98, No. 5, USA.
E.B De Souza, “Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role In Central Nervous System and Immune Disorders”,Psychoneuroendocrinology, 1995, 789-819, vol. 20, No. 8, Elsevier Science Ltd., USA.
D.T. Chalmers, et al., “Corticotropin-releasing factor receptors: from molecular biology to drug design”,TiPS, Apr. 1996, 166-172, vol. 17, Elsevier Science Ltd., USA.
E.T. Wei, et al., “Peripheral anti-inflammatory actions of corticotropin-releasing factor”,Ciba Foundation Symposium 172, 1993, 258-276, Wiley, Chichester.
J.R. McCarthy, et al., “Recent Advances with the CRF1Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications”,Current Pharmaceutical Design, 1999, 289-315, vol. 5, Bentham Science Publishers B.V.
G.P. Chrousos, et al., “Corticotropin Releasing Factor: Basic Studies and Clinical Applications”,Prog. Neuro-Psychopharmacol. &Biol. Psychiat., 1985, 349-359, vol. 9, Pergamon Press Ltd., Great Britain.
G.B. Cutler, Jr., M.D., “Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use”,The Endocrinologist, 1997, 10S-16S, vol. 7, No. 1, Suppl. 1, Williams & Wilkins.
M.J. Owens, et al., “Physiology and Pharmacology of Corticotropin-releasing Factor”,Pharmacological Reviews, 1991, 425-473, vol. 43, No. 4, The American Society for Pharmacology and Experimental Therapeutics, USA.
L. Arborelius, et al., “The role of corticotropin-releasing factor in depression and anxiety disorders”,Journal of Endocrinology, 1999, 1-12, vol. 160, Society for Endocrinology, Great Britain.
D.N. Orth, “Corticotropin-Releasing Hormone in Humans”,Endocrine Reviews, 1992, 164-191, vol. 13, No. 2, The Endocrine Society, USA.
E. Emeric-Sauval, “Corticotropin-Releasing Factor (CRF)—A Review”,Psychoneuroendocrinology, 1985, 277-294, vol. 11, No. 3, Pergamon Journals Ltd., Great Britain.
J. Spiess, et al., “Molecular Properties of the CRF Receptor”,TEM, 1998, 140-145, vol. 9, No. 4, Elsevier Science Ltd.
K.D. Dieterich, et al., “Corticotropin-releasing factor receptors: An overview”,Exp. Clin. Endocrinol. Diabetes, 1997, 65-82, vol. 105, Johann Ambrosius Barth.
P.J. Gilligan, et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents”,Journal of Medicinal Chemistry, May 4, 2000, 1641-1660, vol. 43, No. 9, American Chemical Society.
C.A. Maltin, et al., “Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients”,Clinical Science, 1993, 651-654, vol. 84.
J.F. Signorile, et al., “Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effect of Beta-2 Adrenergic Agonist”,Arch Phys Med Rehabil, 1995, 55-58, vol. 76.
L. Martineau, et al., “Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men”,Clinical Science, 1992, 615-621, vol. 83.
Medler, S., “Comparative trends in shortening velocity and force production in skeletal muscles”,Am. J. Physiol Regulatory Integrative Comp Physiol, 2002, vol. 283, pp. R368-R378.
Rome, L.C., “The Design of Vertebrate Muscular Systems: Comparative and Integrative Approaches”,Clinical Orthopaedics and Related Research, 2002, No. 403S, pp. S59-S76.
H.A. Thomas, et al., “CRF and Related Peptides as Anti-Inflammatory Agonists”,Annals New York Academy of Sciences, 1993, vol. 697, pp. 219-228.
.R. McCarthy, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents”,Annual Reports in Medicinal Chemistry, 1999, vol. 34, Academic Press, pp. 11-20.
Isfort Robert Joseph
Sheldon Russell James
Desai Naishadh N.
Kemmerer Elizabeth
Shafer Shulamith H
The Procter & Gamble & Company
LandOfFree
Methods for identifying compounds for regulating muscle mass... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying compounds for regulating muscle mass..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying compounds for regulating muscle mass... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3633533